What's The Latest Update For Non-Invasive TMVR? www.heart-valve-surgery.com May 8, 2022, 9 p.m.
The impact of transcatheter aortic valve replacement (TAVR) for aortic stenosis patients has been revolutionary during the past 10 years. TAVR does not require an incision to the patient’s chest or ribs. A TAVR procedure does not require the use of the heart-lung machine. And, TAVR patients are often in the hospital for only one day. With the success of TAVR, patients with mitral valve disease are asking questions about the use of transcatheter mitral valve repair (TMVr) and transcatheter mitral valve replacement (TMVR). For example, I just received an email from Henry who asked me, “Hi Adam, What is the latest update for transcatheter mitral valve treatments?”
Surgeon Q&A: What's The Latest Update For Non-Invasive TMVR? www.heart-valve-surgery.com May 8, 2022, 9 p.m.
The impact of transcatheter aortic valve replacement (TAVR) for aortic stenosis patients has been revolutionary during the past 10 years. TAVR does not require an incision to the patient’s chest or ribs. A TAVR procedure does not require the use of the heart-lung machine. And, TAVR patients are often in the hospital for only one day.With the success of TAVR, patients with mitral valve disease are asking questions about the use of transcatheter mitral valve repair (TMVr) and transcatheter mitral valve replacement (TMVR). For example, I just received an email from Henry who asked me, “Hi Adam, What is the latest update for transcatheter mitral valve treatments?”
Multicenter Clinical Management Practice to Optimize Outcomes Following Tendyne Transcatheter Mitral Valve Replacement www.structuralheartjournal.org May 8, 2022, 8:59 p.m.
The TendyneTM transcatheter mitral valve replacement system (Tendyne-TMVR, Abbott Structural Heart, Santa Clara, California) is a therapy for patients with symptomatic mitral valve (MV) disease high risk for conventional MV surgery or challenging anatomy for transcatheter MV repair. With over 1000 Tendyne-TMVR performed worldwide and beneficial periprocedural, 30-day, and 2-year outcomes, the aim of this article is to present best practice recommendations from expert centers performing Tendyne-TMVR to support optimal outcomes (Figure 1).
First successful “valve-in-MAC” transcatheter mitral valve replacement nortonhealthcareprovider.com May 8, 2022, 8:57 p.m.
A multidisciplinary team of interventional cardiologists and a cardiothoracic surgeon performed Louisville’s first successful transcatheter replacement of a native mitral valve this week. The team with Norton Heart & Vascular Institute Structural Heart Program used a transcatheter aortic valve (commonly referred to as TAVR) to replace the patient’s mitral valve that was unable to be treated with standard techniques.
Endoaortic Balloon Occlusion During Minimally Invasive Mitral Valve Surgery journals.sagepub.com May 8, 2022, 8:28 p.m.
Common practice in the treatment of pathologies affecting the atrioventricular valves has evolved in the recent past. The current approach is minimlly invasive cardiac surgery through a right (antero)lateral minithoracotomy, and aortic cross-clamping is performed by way of 2 internationally accepted techniques: endoaortic balloon occlusion with an inflatable balloon or the external transthoracic aortic cross-clamp. The endoaortic balloon occlusion catheter is positioned into the ascending aorta above the sinotubular junction through the common femoral artery. There are 3 lumina at the tip of the balloon occlusion catheter. One lumen is for the balloon inflation and deflation, 1 is for monitoring aortic root pressure, and 1 is for the delivery of cardioplegia. Should the ascending aorta diameter be >42 mm, balloon placement is a contraindication.
Pulmonary Hypertension in Mitral Regurgitation www.ahajournals.org May 8, 2022, 9:09 a.m.
Mitral regurgitation (MR) is the most common valvular lesion in the United States and the second‐most common valvular lesion requiring surgery in Europe. In the United States, over 2.5 million people are estimated to have moderate‐to‐severe MR, and this number is expected to double by 2030. Over the past several decades, improvements in our ability to diagnose and quantify MR, coupled with a better understanding of its natural history and the adverse prognostic features, has led to the refinement of indications for mitral valve surgery. Pulmonary hypertension (defined as a systolic pressure >50 mm Hg at rest or >60 mm Hg with exercise) is one such adverse prognostic indicator, the presence of which in patients with asymptomatic MR translates to a class IIA indication for mitral valve surgery according to the latest American College of Cardiology/American Heart Association (ACC/AHA) and European Society of Cardiology (ESC) guidelines. Pulmonary hypertension has long been known to be a serious complication of mitral valve disease (MVD). Yet, its precise role in the natural history and management of patients with MR remains scantly investigated, as exemplified by a level of evidence C associated with the above‐mentioned recommendation for surgery.
A Simulation Study of the Effects of Number and Location of MitraClips on Mitral Regurgitation www.jacc.org April 3, 2022, 10:37 a.m.
MitraClip (MC) is a device that is implanted on the mitral valve (MV) percutaneously to treat severe mitral regurgitation (MR). It is common practice to place the MCs at the site of the most significant MR jets identified by echocardiography.
FDA Approves Edwards' Mitris Resilia Surgical Mitral Valve www.mpo-mag.com April 3, 2022, 10:33 a.m.
Mitris Resilia’s saddle-shaped sewing cuff mimic’s the native mitral valves asymmetric shape. Its low-profile frame helps avoid left ventricular outflow tract obstruction by stent posts and is visible under fluoroscopy, helping future transcatheter innovations. Resilia bovine pericardial tissue is the platform for Edwards’ new class of valves. It has been studied in two premarket clinical trials in both the U.S. and Europe. The studies together represent outcomes on 904 patients and over 3,800 patient years of followup once completed.
4C Medical Technologies completes a $35 Million series C funding round led by MicroPort www.nsmedicaldevices.com April 3, 2022, 10:29 a.m.
4C Medical Technologies, a privately-held medical technology company focused on the development of minimally invasive therapies for structural heart disease, announced that it has completed a $35.4 million Series C Preferred Stock financing. The Series C round was led by MicroPort CardioFlow Medtech Corporation.
SafeCross transseptal balloon gets first commercial use cardiovascularnews.com April 3, 2022, 10:27 a.m.
East End Medical has announced the first commercial use of its SafeCross transseptal radiofrequency (RF) puncture and steerable balloon introducer system. The system is designed to provide a predictable and safe solution for performing electrophysiology and structural heart interventions requiring left atrial access, the company said in a press release.
Xeltis - Endogenous Tissue Restoration xeltis.com March 28, 2022, 4:48 p.m.
Xeltis developed the world’s most advanced polymer-based platform of restorative cardiovascular devices. Xeltis’ devices naturally evolve into living blood vessels or heart valves, when colonized by patient’s own tissue. This therapeutic approach is called Endogenous Tissue Restoration (ETR).
Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation www.thelancet.com March 28, 2022, 1:07 p.m.
Severe mitral regurgitation is associated with impaired prognosis if left untreated. Using the devices currently available, transcatheter mitral valve repair (TMVr) remains challenging in complex anatomical situations. We report the procedural and 30-day results of the first-in-man study of the Edwards PASCAL TMVr system.
Prognostic Value of Creatine Phosphate and Inflammatory Markers for Mitral Valve Replacement www.hindawi.com March 28, 2022, 9:11 a.m.
The prognosis of mitral valve replacement is an important clinical issue and may produce unexpected mortality rates if not properly addressed. The postoperative examination results have important prognostic implications. This study was designed to determine the prognostic value of phosphocreatine and inflammatory markers after mitral valve replacement.
Long-Term Outcomes of Mosaic Versus Perimount Mitral Replacements: 17-Year Follow-Up of 940 Implants pubmed.ncbi.nlm.nih.gov March 20, 2022, 5:05 p.m.
In long-term follow-up, of patients younger than 65 years of age undergoing mitral valve replacement, bovine pericardial valves experienced earlier and more frequent structural valve deterioration than porcine valves.
Transcatheter edge-to-edge mitral valve repair in patients with mitral annulus calcification eurointervention.pcronline.com March 20, 2022, 5:03 p.m.
MitraClip use in selected patients with moderate or severe MAC is safe, feasible and achieves good clinical and echocardiographic results at one-year follow-up.
Procedural and clinical outcomes after repeat edge-to-edge transcatheter mitral valve repair pubmed.ncbi.nlm.nih.gov March 14, 2022, 7:41 a.m.
According to our findings, redo edge-to-edge TMVR interventions were feasible and safe with a high procedural success rate. Clinical and echocardiographic follow-up showed however modest long-term results in this specific setting.
Patient selection for trans-catheter mitral valve repair vs replacement vpjournal.net March 14, 2022, 7:40 a.m.
Percutaneous procedures can be considered a safe alternative to surgical approaches in most patients affected by severe mitral regurgitation (MR). Although transcatheter mitral valve repair (TMVR) is currently the first choice in most clinical settings, transcatheter mitral valve replacement (TMVRpl) will increasingly be a complementary technique in the near future. Several devices have been approved or are under investigation, permitting a customized strategy based on clinical and anatomical factors.
CRT 2022: Novel transfemoral mitral valve repair technology wins innovation competition cardiovascularnews.com March 14, 2022, 7:38 a.m.
According to NeoChord, the Nexus transcatheter mitral chordal repair device is unique from other mitral valve repair technologies in maintaining a natural physiologic functionality of the mitral valve. It is deployed through the vein using a transfemoral delivery catheter, navigated transeptally to the diseased native mitral valve. Due to minimal hardware used and the proven leaflet connection, NeoChord Nexus preserves options for patients who may need reintervention in the future.
Keeping it simple but not simpler: the pros and cons of deep sedation versus general anaesthesia for percutaneous mitral valve repair eurointervention.pcronline.com March 13, 2022, 9:25 a.m.
Since its inception in 2003, percutaneous edge-to-edge mitral valve repair (PMVR) for mitral regurgitation has experienced explosive growth, with >100,000 procedures performed globally to date. The vast majority of these procedures have long been performed with the patient under general anaesthesia (GA); only a disproportionate fraction of patients is being treated under deep sedation (DS).